Clinical implications of overweight regarding response and survival in locally advanced cervical cancers treated with curative chemoradiation: a retrospective and multi-institutional research

A multi-institutional investigation was conducted to investigate the impacts of overweight on the outcomes of locally advanced cervical cancers (LACC) treated by curative chemoradiation. Based on their body mass index (BMI), the patients were classified into an overweight (BMI, 25–29.9) or normal (BMI, 18.5–24.9) group. Parametric statistics were used to balance their baseline and treatment-related characteristics. The primary outcome was tumor response, and secondary outcomes were overall survival (OS) and disease-free survival (DFS). Univariate and multivariate logistic regressions were performed to test the contribution of overweight as a risk factor. Of the 707 patients enrolled, 228 were assigned to the overweight group and 479 to the normal group. The findings showed that the objective response rate (ORR) and disease control rate (DCR) of the overweight group was notably decreased as compared to normal group (50.0% vs. 58.5%, p = 0.03; 67.1% vs. 76.2%, p = 0.01, respectively). The median DFS of the overweight and normal groups were 34.0 and 35.0 months, respectively, with an hazard rate (HR) of 1.09 (95% confidence interval (CI): 0.87–1.36, p = 0.42). Moreover, the median OS of the overweight and normal groups were 49.0 and 52.0 months, respectively, with an HR of 1.22 (95% CI: 0.97–1.53, p = 0.06). Univariate analysis revealed that overweight was independently associated with poor ORR (odds ratio (OR): 0.710, 95% CI: 0.517–0.975; p = 0.035) and DCR (OR: 0.629, 95% CI: 0.444–0.891; p = 0.009), which was confirmed in multivariate logistic regression (OR: 0.564, 95% CI: 0.402–0.793, p = 0.001; OR: 0.513, 95% CI: 0.354–0.742, p = 0.001, respectively). To be summarized, overweight is characterized as an independent factor of poor response for curative chemoradiation, underscoring the importance of stratifying patients based on BMI during the LACC treatment process.

Overweight; Cervical cancer; Chemoradiation; Response; Survival

[1] Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chinese Journal of Cancer Research. 2020; 32: 720–728.

[2] Dong Y, Zhou J, Zhu Y, Luo L, He T, Hu H, et al. Abdominal obesity and colorectal cancer risk: systematic review and meta-analysis of prospective studies. Bioscience Reports. 2017; 37: BSR20170945.

[3] Picon-Ruiz M, Morata-Tarifa C, Valle-Goffin JJ, Friedman ER, Slinger-land JM. Obesity and adverse breast cancer risk and outcome: Mecha-nistic insights and strategies for intervention. CA: a Cancer Journal for Clinicians. 2017; 67: 378–397.

[4] Zhu C, Qu J, Cao H, Chen G, Shi Y, Fan J. Obesity and nonalcoholic fatty liver disease associated with adenocarcinoma in patients with lung cancer. Medicine. 2019; 98: e17098.

[5] Dalmartello M, Vermunt J, Negri E, Levi F, La Vecchia C. Adult lifetime body mass index trajectories and endometrial cancer risk. BJOG: an International Journal of Obstetrics & Gynaecology. 2022; 129: 1521–1529.

[6] Zamorano AS, Hagemann AR, Morrison L, Lee JA, Liao LM, Brinton LA, et al. Pre-diagnosis body mass index, physical activity and ovarian cancer mortality. Gynecologic Oncology. 2019; 155: 105–111.

[7] Clark LH, Jackson AL, Soo AE, Orrey DC, Gehrig PA, Kim KH. Extremes in body mass index affect overall survival in women with cervical cancer. Gynecologic Oncology. 2016; 141: 497–500.

[8] Hopkins MP, Morley GW. Prognostic factors in advanced stage squamous cell cancer of the cervix. Cancer. 1993; 72: 2389–2393.

[9] Lee J, Chang C, Lin J, Wu M, Sun F, Wu C, et al. The effect of body mass index and weight change on late gastrointestinal toxicity in locally advanced cervical cancer treated with intensity-modulated radiotherapy. International Journal of Gynecologic Cancer. 2018; 28: 1377–1386.

[10] Lee J, Chang C, Lin J, Wu M, Sun F, Wu C, et al. The effect of body mass index and weight change on late gastrointestinal toxicity in locally advanced cervical cancer treated with intensity-modulated radiotherapy. International Journal of Gynecologic Cancer. 2018; 28: 1377–1386.

[11] Pareek V, Barthwal M, Giridhar P, Patil PA, Upadhyay AD, Mallick S. A phase III randomised trial of trans-abdominal ultrasound in improving application quality and dosimetry of intra-cavitary brachytherapy in locally advanced cervical cancer. Gynecologic Oncology. 2021; 160: 375–378.

[12] Kitagawa R, Katsumata N, Shibata T, Kamura T, Kasamatsu T, Nakanishi T, et al. Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. Journal of Clinical Oncology. 2015; 33: 2129–2135.

[13] Alimena S, Yang DD, Melamed A, Mahal BA, Worley MJ, Feldman S, et al. Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. Gynecologic Oncology. 2019; 154: 595–601.

[14] Robin TP, Amini A, Schefter TE, Behbakht K, Fisher CM. Disparities in standard of care treatment and associated survival decrement in patients with locally advanced cervical cancer. Gynecologic Oncology. 2016; 143: 319–325.

[15] Frumovitz M, Jhingran A, Soliman PT, Klopp AH, Schmeler KM, Eifel PJ. Morbid obesity as an independent risk factor for disease-specific mortality in women with cervical cancer. Obstetrics & Gynecology. 2014; 124: 1098–1104.

[16] Kizer NT, Thaker PH, Gao F, Zighelboim I, Powell MA, Rader JS, et al. The effects of body mass index on complications and survival outcomes in patients with cervical carcinoma undergoing curative chemoradiation therapy. Cancer. 2011; 117: 948–956.

[17] McDade TW, Meyer JM, Koning SM, Harris KM. Body mass and the epidemic of chronic inflammation in early mid-adulthood. Social Science & Medicine. 2021; 281: 114059.

[18] Bekkelund SI, Jorde R. Lean body mass and creatine kinase are associated with reduced inflammation in obesity. European Journal of Clinical Investigation. 2017; 47: 803–811.

[19] Oddy WH, Allen KL, Trapp GSA, Ambrosini GL, Black LJ, Huang R, et al. Dietary patterns, body mass index and inflammation: Pathways to depression and mental health problems in adolescents. Brain, Behavior, and Immunity. 2018; 69: 428–439.

[20] Fayanju OM, Hall CS, Bauldry JB, Karhade M, Valad LM, Kuerer HM, et al. Body mass index mediates the prognostic significance of circulating tumor cells in inflammatory breast cancer. The American Journal of Surgery. 2017; 214: 666–671.

[21] Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prevention Research. 2011; 4: 1021–1029.

[22] Gallagher EJ, LeRoith D. The proliferating role of insulin and insulin-like growth factors in cancer. Trends in Endocrinology & Metabolism. 2010; 21: 610–618.

[23] Park JK, Park HA, Park JJ, Cho YG. Obesity and screening compliance for breast and cervical cancer in Korean women. Asian Pacific Journal of Cancer Prevention. 2012; 13: 3271–3274.

[24] Martín-López R, Hernández-Barrera V, de Andres AL, Carrasco-Garrido P, de Miguel AG, Jimenez-Garcia R. Trend in cervical cancer screening in Spain (2003–2009) and predictors of adherence. European Journal of Cancer Prevention. 2012; 21: 82–88.